Using multiple cytokines to predict hepatocellular carcinoma recurrence in two patient cohorts

British Journal of Cancer

Volumn 110, Issue 3, 2014, Pages 733-740

  Chen, Z Y ^a,b   Wei, W ^a   Guo, Z X ^a   Peng, L X ^a   Shi, M ^a   Li, S H ^a   Xiao, C Z ^a,c   Zhong, C ^d   Qian, C N ^a   Guo, R P ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c GUANGZHOU MEDICAL UNIVERSITY   (China)

^d GUANGZHOU UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

cytokines; hepatocellular carcinoma; prognosis; radical resection

Indexed keywords

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; CYTOKINES; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS;

EID: 84893760158     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.781     Document Type: Article

References (37)

1. An HJ, Jang JW, Bae SH, Choi JY, Cho SH, Yoon SK, Han JY, Lee KH, Kim DG, Jung ES (2010) Sustained low hepatitis B viral load predicts good outcome after curative resection in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 25(12): 1876-1882.
2. Arzumanyan A, Helena MG, Reis HM, Feitelson MA (2013) Pathogenic mechanisms in HBV-and HCV-associated hepatocellular carcinoma. Nat Rev Cancer 13(2): 123-135.
3. Ayyappan AP, Jhaveri KS (2010) CT and MRI of hepatocellular carcinoma: an update. Expert Rev Anticancer Ther 10(4): 507-519.
4. Balkwill F (2004) Cancer and the chemokine network. Nat Rev Cancer 4(7): 540-550.
5. Bruix J, Llovet JM (2009) Major achievements in hepatocellular carcinoma. Lancet 373(9664): 614-616.
6. Cahlin C, Korner A, Axelsson H, Wang W, Lundholm K, Svanberg E (2000) Experimental cancer cachexia: the role of host-derived cytokines interleukin (IL)-6, IL-12, interferon-gamma, and tumor necrosis factor alpha evaluated in gene knockout, tumor-bearing mice on C57 Bl background and eicosanoid-dependent cachexia. Cancer Res 60(19): 5488-5493.
7. Capone F, Costantini S, Guerriero E, Calemma R, Napolitano M, Scala S, Izzo F, Castello G (2010) Serum cytokine levels in patients with hepatocellular carcinoma. Eur Cytokine Netw 21(2): 99-104.
8. Chan HL, Sung JJ (2006) Hepatocellular carcinoma and hepatitis B virus. Semin Liver Dis 26(2): 153-161.
9. Chen WQ, Zheng RS, Zhang SW (2013) Liver cancer incidence and mortality in China, 2009. Chin J Cancer 32(4): 162-169.
10. Chen ZY, Shi M, Peng LX, Wei W, Li XJ, Guo ZX, Li SH, Zhong C, Qian CN, Guo RP (2012) Dovitinib preferentially targets endothelial cells rather than cancer cells for the inhibition of hepatocellular carcinoma growth and metastasis. J Transl Med 10: 245.
11. Chen ZY, Wei W, Guo ZX, Lin JR, Shi M, Guo RP (2011) Morphologic classification of microvessels in hepatocellular carcinoma is associated with the prognosis after resection. J Gastroenterol Hepatol 26(5): 866-874.
12. Foster JH (1984) Computing operative risk. Surgery 95(5): 631.
13. Gourzones C, Barjon C, Busson P (2012) Host-tumor interactions in nasopharyngeal carcinomas. Semin Cancer Biol 22(2): 127-136.
14. Hanley JA (1989) Receiver operating characteristic (ROC) methodology: the state of the art. Crit Rev Diagn Imaging 29(3): 307-335.
15. Hsu CY, Hsia CY, Huang YH, Su CW, Lin HC, Lee PC, Loong CC, Chiang JH, Huo TI, Lee SD (2010) Selecting an optimal staging system for hepatocellular carcinoma: comparison of 5 currently used prognostic models. Cancer 116(12): 3006-3014.
16. Huitzil-Melendez FD, Capanu M, O'Reilly EM, Duffy A, Gansukh B, Saltz LL, Abou-Alfa GK (2010) Advanced hepatocellular carcinoma: which staging systems best predict prognosis? J Clin Oncol 28(17): 2889-2895.
17. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2): 69-90.
18. Levina V, Su Y, Nolen B, Liu X, Gordin Y, Lee M, Lokshin A, Gorelik E (2008) Chemotherapeutic drugs and human tumor cells cytokine network. Int J Cancer 123(9): 2031-2040.
19. Li XP, Cao GW, Sun Q, Yang C, Yan B, Zhang MY, Fu YF, Yang LM (2012) Cancer incidence and patient survival rates among residents in the Pudong New Area of Shanghai between 2002 and 2006. Chin J Cancer 32(9): 512-519.
20. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4): 378-390.
21. Lu W, Dong J, Huang Z, Guo D, Liu Y, Shi S (2008) Comparison of four current staging systems for Chinese patients with hepatocellular carcinoma undergoing curative resection: Okuda, CLIP, TNM and CUPI. J Gastroenterol Hepatol 23(12): 1874-1878.
22. Luan F, Liu H, Gao L, Liu J, Sun Z, Ju Y, Hou N, Guo C, Liang X, Zhang L, Sun W, Ma C (2009) Hepatitis B virus protein preS2 potentially promotes HCC development via its transcriptional activation of hTERT. Gut 58(11): 1528-1537.
23. Lurje G, Zhang W, Schultheis AM, Yang D, Groshen S, Hendifar AE, Husain H, Gordon MA, Nagashima F, Chang HM, Lenz HJ (2008) Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer. Ann Oncol 19(10): 1734-1741.
24. Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454(7203): 436-444.
25. Ning Y, Lenz HJ (2012) Targeting IL-8 in colorectal cancer. Expert Opi Ther Targets; e-pub ahead of print 12 April 2012.
26. Niu J, Azfer A, Zhelyabovska O, Fatma S, Kolattukudy PE (2008) Monocyte chemotactic protein (MCP)-1 promotes angiogenesis via a novel transcription factor, MCP-1-induced protein (MCPIP). J Biol Chem 283(21): 14542-14551.
27. op den Winkel M, Nagel D, Sappl J, op den Winkel P, Lamerz R, Zech CJ, Straub G, Nickel T, Rentsch M, Stieber P, Goke B, Kolligs FT (2012) Prognosis of patients with hepatocellular carcinoma. Validation and ranking of established staging-systems in a large western HCC-cohort. PLoS One 7(10): e45066.
28. Seruga B, Zhang H, Bernstein LJ, Tannock IF (2008) Cytokines and their relationship to the symptoms and outcome of cancer. Nat Rev Cancer 8(11): 887-899.
29. Spira A, Ettinger DS (2004) Multidisciplinary management of lung cancer. N Engl J Med 350(4): 379-392.
30. Toyosaka A, Okamoto E, Mitsunobu M, Oriyama T, Nakao N, Miura K (1996) Intrahepatic metastases in hepatocellular carcinoma: evidence for spread via the portal vein as an efferent vessel. Am J Gastroenterol 91(8): 1610-1615.
31. Vingerhoets J, Michielsen P, Vanham G, Bosmans E, Paulij W, Ramon A, Pelckmans P, Kestens L, Leroux-Roels G (1998) HBV-specific lymphoproliferative and cytokine responses in patients with chronic hepatitis B. J Hepatol 28(1): 8-16.
32. Wang B, Hendricks DT, Wamunyokoli F, Parker MI (2006) A growth-related oncogene/CXC chemokine receptor 2 autocrine loop contributes to cellular proliferation in esophageal cancer. Cancer Res 66(6): 3071-3077.
33. Wu MH, Hong HC, Hong TM, Chiang WF, Jin YT, Chen YL (2011) Targeting galectin-1 in carcinoma-associated fibroblasts inhibits oral squamous cell carcinoma metastasis by downregulating MCP-1/CCL2 expression. Clin Cancer Res 17(6): 1306-1316.
34. Wu WK, Llewellyn OP, Bates DO, Nicholson LB, Dick AD (2010) IL-10 regulation of macrophage VEGF production is dependent on macrophage polarisation and hypoxia. Immunobiology 215(9-10): 796-803.
35. Xu J, Ding T, He Q, Yu XJ, Wu WC, Jia WH, Yun JP, Zhang Y, Shi M, Shao CK, Pan WD, Yin XY, Min J, Zhuang SM, Zheng L (2012) An in situ molecular signature to predict early recurrence in hepatitis B virus-related hepatocellular carcinoma. J Hepatol 57(2): 313-321.
36. Zhu ZH, Sun BY, Ma Y, Shao JY, Long H, Zhang X, Fu JH, Zhang LJ, Su XD, Wu QL, Ling P, Chen M, Xie ZM, Hu Y, Rong TH (2009) Three immunomarker support vector machines-based prognostic classifiers for stage IB non-small-cell lung cancer. J Clin Oncol 27(7): 1091-1099.
37. Zlobec I, Steele R, Terracciano L, Jass JR, Lugli A (2007) Selecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer. J Clin Pathol 60(10): 1112-1116.